Grant: Alliance Grants
York University
$50,000.00
Development of Rapid and Accessible Diagnostics of COVID-19 via Aptamer-Based Detection of SARS-COV-2 Virions_x000d_ _x000d_ _x000d_ _x000d_ _x000d_
FY 2020-21
Summary
Effectively dealing with the ongoing COVID-19 pandemic and preventing future COVID outbreaks require rapid and accessible detection of the virus in all individuals suspected of having active injection. The current flagship method for diagnosing COVID-19 is based on detection of vial RNA. It is sensitive and specific, but it has quickly proved to be inadequate for COVID-19 epidemics as it is slow and requires highly-specialized facilities. Here we propose fast and accessible diagnosis via detection of viral particles. The proposed diagnostics will be facilitated by DNA aptamers which can selectively bind viral particles and label them for highly sensitive detection. To implement this challenging approach, we partner with the leading COVID-19 testing facilities at the Hospital for Sick Children and Mount Sinai Hospital in Toronto. This partnership has all required expertise and facilities to successfully complete the project by the end of the one-year term. We will also be assisted by SCIEX, a company in Toronto that produces analytical instrumentation used in our research and our long-term partner. Our research plan is concrete and realistic and is expected to lead to concrete clinically-tested SARS-Cov-2 detection schemes.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
555236-2020
Name nom
Krylov, Sergey
Department département
Chemistry
Organization id
38
Institution établissement
York University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
50000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Development of Rapid and Accessible Diagnostics of COVID-19 via Aptamer-Based Detection of SARS-COV-2 Virions_x000d_
_x000d_
_x000d_
_x000d_
_x000d_
Keyword
NSERC
Application summary
Effectively dealing with the ongoing COVID-19 pandemic and preventing future COVID outbreaks require rapid and accessible detection of the virus in all individuals suspected of having active injection. The current flagship method for diagnosing COVID-19 is based on detection of vial RNA. It is sensitive and specific, but it has quickly proved to be inadequate for COVID-19 epidemics as it is slow and requires highly-specialized facilities. Here we propose fast and accessible diagnosis via detection of viral particles. The proposed diagnostics will be facilitated by DNA aptamers which can selectively bind viral particles and label them for highly sensitive detection. To implement this challenging approach, we partner with the leading COVID-19 testing facilities at the Hospital for Sick Children and Mount Sinai Hospital in Toronto. This partnership has all required expertise and facilities to successfully complete the project by the end of the one-year term. We will also be assisted by SCIEX, a company in Toronto that produces analytical instrumentation used in our research and our long-term partner. Our research plan is concrete and realistic and is expected to lead to concrete clinically-tested SARS-Cov-2 detection schemes.
